The genetic basis of variability in drug responses

被引：183

作者：

Roden, DM

George, AL

机构：

[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2002年 / 1卷 / 01期

关键词：

D O I：

10.1038/nrd705

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

It is almost axiomatic that patients vary widely in their beneficial responses to drug therapy, and serious and apparently unpredictable adverse drug reactions continue to be a major public health problem. Here, we discuss the concept that genetic variants might determine much of this variability in drug response, and propose an algorithm to enable further evaluation of the benefits and pitfalls of this enticing possibility.

引用

页码：37 / 44

页数：8

共 81 条

[61] Orphan receptor promiscuity in the induction of cytochromes P450 by xenobiotics [J].

Smirlis, D ;

Muangmoonchai, R ;

Edwards, M ;

Phillips, IR ;

Shephard, EA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :12822-12826

[62] Haplotype variation and linkage disequilibrium in 313 human genes [J].

Stephens, JC ;

Schneider, JA ;

Tanguay, DA ;

Choi, J ;

Acharya, T ;

Stanley, SE ;

Jiang, RH ;

Messer, CJ ;

Chew, A ;

Han, JH ;

Duan, JC ;

Carr, JL ;

Lee, MS ;

Koshy, B ;

Kumar, AM ;

Zhang, G ;

Newell, WR ;

Windemuth, A ;

Xu, CB ;

Kalbfleisch, TS ;

Shaner, SL ;

Arnold, K ;

Schulz, V ;

Drysdale, CM ;

Nandabalan, K ;

Judson, RS ;

Ruaño, G ;

Vovis, GF .

SCIENCE, 2001, 293 (5529) :489-493

[63]

Stolk JN, 1998, ARTHRITIS RHEUM-US, V41, P1858, DOI 10.1002/1529-0131(199810)41:10<1858::AID-ART19>3.3.CO

[64]

2-#

[65] The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism [J].

SullivanKlose, TH ;

Ghanayem, BI ;

Bell, DA ;

Zhang, ZY ;

Kaminsky, LS ;

Shenfield, GM ;

Miners, JO ;

Birkett, DJ ;

Goldstein, JA .

PHARMACOGENETICS, 1996, 6 (04) :341-349

[66] The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux [J].

Synold, TW ;

Dussault, I ;

Forman, BM .

NATURE MEDICINE, 2001, 7 (05) :584-590

[67] HMG-CoA reductase inhibitors and myotoxicity [J].

Ucar, M ;

Mjörndal, T ;

Dahlqvist, R .

DRUG SAFETY, 2000, 22 (06) :441-457

[68] ACE (I/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans [J].

Ueda, S ;

Meredith, PA ;

Morton, JJ ;

Connell, JMC ;

Elliot, HL .

CIRCULATION, 1998, 98 (20) :2148-2153

[69] TRICYCLIC ANTIDEPRESSANT PLASMA-LEVELS AFTER FLUOXETINE ADDITION [J].

VANDEL, S ;

BERTSCHY, G ;

BONIN, B ;

NEZELOF, S ;

FRANCOIS, TH ;

VANDEL, B ;

SECHTER, D ;

BIZOUARD, P .

NEUROPSYCHOBIOLOGY, 1992, 25 (04) :202-207

[70] GENETIC CONTROL OF DRUG LEVELS IN MAN - ANTIPYRINE [J].

VESELL, ES ;

PAGE, JG .

SCIENCE, 1968, 161 (3836) :72-&

← 1 2 3 4 5 6 7 8 9 →